<DOC>
	<DOCNO>NCT01991158</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety High dose Methotrexate combine gemcitabine , pegaspargase dexamethasone ( GAD-M regimen ) first-line treatment patient de novo extranodal NK/T cell lymphoma .</brief_summary>
	<brief_title>GAD-M Regimen As First-Line Treatment Untreated Extranodal NK/T Cell Lymphoma</brief_title>
	<detailed_description>Studies show effect P glycoprotein mediate chemotherapy resistance reduce therapeutic efficacy anthracycline-based chemotherapy NK/T cell lymphoma , agent like pegaspargase large dos Methotrexate affect P glycoprotein . A number report suggest gemcitabine combine chemotherapy drug good application prospect treatment lymphoma . Dexamethasone use combination agent treatment lymphoma may implicate development growth cancer . So explored evaluate efficacy safety High dose methotrexate combine gemcitabine , pegaspargase dexamethasone ( GAD-M regimen ) first-line treatment patient untreated extranodal NK/T cell lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>Histologic diagnosis NK/T Cell Lymphoma ; Age:1880 year ; Weight：Male：67±20Kg（4787Kg），Female：55±20Kg（3575Kg） Eastern Cooperative Oncology Group ( ECOG ) status 03 , Estimated survival time &gt; 3 month ; No history malignancy ; No current tumors； Normal haematological , liver renal function ( WBC count≥3.5×109/L , Hemoglobin≥100g/L , platelet count≥90×109/L , bilirubin＜1.5×ULN , Alanine transaminase ( ALT ) Aspartate Aminotransferase ( AST ) ＜2.5×ULN , serum creatinine＜1.5×ULN ) , normal coagulation function cardiac function ; Clinical stag IIV； No previous treatment include chemotherapy , radiotherapy , target therapy stem cell transplantation ; Appreciable measurable lesion , clinical assessment ＞2cm，CT MRI ＞1.5cm ; No serious disease conflict treatment present trial ; No concurrent treatment conflict treatment present trial ( include steroid drug ) ; Voluntary participation sign informed consent . The patient condition : clinically significant ventricular tachycardia ( VT ) , atrial fibrillation ( AF ) , heart block , myocardial infarction ( MI ) , congestive heart failure ( CHF ) , symptomatic coronary artery heart disease require medication ; The patient suffer organ transplant The patient participate clinical trial within 30 day enrollment participate clinical study ; The patient active bleed new thrombotic disease , take anticoagulant drug history bleeding tendencies，who active infection ; The patient suffer surgery less four week , less six week ; The patient abnormal liver function ( total bilirubin &gt; 1.5 time normal value , ALT / AST &gt; 2.5 time normal ) , abnormal renal function ( serum creatinine &gt; 1.5 time normal ) , blood abnormality ( absolute neutrophil count &lt; 1.5 × 109 / L , platelets &lt; 80 × 109 / L , hemoglobin &lt; 90g /L ) ; The patient mentally ill / unable obtain informed consent ; The patient drug addiction , alcohol abuse affect longterm evaluation test result ; The patient pregnancy , lactation woman childbearing age want take contraceptive measure subject ; Clinical laboratory support brain metastasis ; The patient history allergy adverse reaction ( ) test drug ; The patient suitable participate investigator judge researcher .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>GAD-M regimen</keyword>
	<keyword>first line chemotherapy</keyword>
	<keyword>NK/T-cell Lymphoma</keyword>
</DOC>